A major milestone in this area was reached on February 16, 2024, when the FDA granted accelerated approval to lifileucel (Amtagvi) by Iovance Biotherapeutics, Inc, San Carlos, CA, USA adoptive cell therapy using autologous tumour-infiltrating lymphocytes (TILs), for adult patients with advanced or unresectable melanoma progressing after prior treatment with immune checkpoint inhibitors and BRAF/MEK inhibitors if BRAF V600 is mutation-positive. The gene discussed is BRAF; the disease is neoplasm.